Genetics

Applied DNA Provides Clarification on Newly Authorized Asymptomatic Serial Screening Indication for LineaTM COVID-19 Assay Kit and Press Release Published 12 May 2021

Friday, May 14, 2021 - 2:51am

Key end-markets include Gov/Mil, textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.\nVisit adnas.com for more information.

Key Points: 
  • Key end-markets include Gov/Mil, textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.\nVisit adnas.com for more information.
  • Follow us on Twitter and LinkedIn .
  • Forward-looking statements describe Applied DNA\xe2\x80\x99s future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA.
  • Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210513006123/en/\n'

Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO)

Thursday, May 13, 2021 - 10:24pm

b'Exicure, Inc.\xc2\xae (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\xe2\x84\xa2) technology, today announced the appointment of Brian C. Bock as the Company\xe2\x80\x99s Chief Financial Officer (CFO) effective immediately.\nThis press release features multimedia.

Key Points: 
  • b'Exicure, Inc.\xc2\xae (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\xe2\x84\xa2) technology, today announced the appointment of Brian C. Bock as the Company\xe2\x80\x99s Chief Financial Officer (CFO) effective immediately.\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210513006058/en/\n\xe2\x80\x9cExicure\xe2\x80\x99s proprietary SNA platform technology holds great potential for treating unmet neurological and rare diseases.
  • I am pleased to be joining such a talented and dedicated team,\xe2\x80\x9d said Mr. Bock, CFO of Exicure.
  • Bock brings over 20 years of life science investment banking, mergers and acquisitions and partnering experience to the Company.

Applied DNA Second Fiscal Quarter 2021 Financial Results Feature 384% Year-Over-Year Growth in Revenues

Thursday, May 13, 2021 - 9:10pm

The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP.

Key Points: 
  • The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP.
  • We use this non-GAAP financial measure for internal financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business.
  • Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not be indicative of our recurring operating results.
  • Forward-looking statements describe Applied DNA\xe2\x80\x99s future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA.

Interline Therapeutics Launches With $92 Million to Map and Correct Dysfunctional Protein Communities

Thursday, May 13, 2021 - 5:00pm

b'Interline Therapeutics , a Foresite Labs incubated company focused on systematically elucidating protein communities to define molecular mechanisms of disease, announced today that the company has raised $92 million.

Key Points: 
  • b'Interline Therapeutics , a Foresite Labs incubated company focused on systematically elucidating protein communities to define molecular mechanisms of disease, announced today that the company has raised $92 million.
  • Medical researchers have been limited by an incomplete understanding of how these communities impact common diseases, lowering the likelihood of successful drug development.\nInterline Therapeutics uses genomics, proteomics, structural biology and computational chemistry to systematically map and modulate protein communities.
  • Company leaders bring decades of experience discovering innovative medicines at Amgen, Denali Therapeutics, Genentech, Novartis and Nurix.
  • Chodera has served as a scientific advisor for and has financial interests in Interline Therapeutics, and has also provided consulting and advisory services to Foresite Labs.

SAB Biotherapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference

Thursday, May 13, 2021 - 3:52pm

b'SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully-human polyclonal antibodies, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will participate in a fireside chat at the RBC Capital Markets 2021 Global Healthcare Conference on Thursday, May 20, 2021 at 11:30 a.m. ET.\nSAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies.

Key Points: 
  • b'SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully-human polyclonal antibodies, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will participate in a fireside chat at the RBC Capital Markets 2021 Global Healthcare Conference on Thursday, May 20, 2021 at 11:30 a.m. ET.\nSAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies.
  • Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, specifically-targeted, high-potency, human polyclonal immunotherapies at commercial scale.
  • In addition to COVID-19, the company\xe2\x80\x99s pipeline also includes programs in Type 1 diabetes, organ transplant, influenza and a human immune globulin (IgG) to treat autoimmune diseases.
  • For more information visit: www.sabbiotherapeutics.com or follow @SABBantibody on Twitter.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210513005720/en/\n'

bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress

Thursday, May 13, 2021 - 1:05pm

In November 2020, bluebird bio submitted to the EMA an application for the second renewal of the CMA.

Key Points: 
  • In November 2020, bluebird bio submitted to the EMA an application for the second renewal of the CMA.
  • This procedure is currently on hold while the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) reviews the safety of ZYNTEGLO.
  • The U.S. Food and Drug Administration (FDA) granted beti-cel Orphan Drug status and Breakthrough Therapy designation for the treatment of TDT.
  • bluebird bio\xe2\x80\x99s clinical development program for LentiGlobin for SCD includes the completed Phase 1/2 HGB-205 study.

Prilenia Achieves 25% Enrollment in its Phase 3 HD Trial and Appoints Dr. Goldberg as CSO

Thursday, May 13, 2021 - 1:00pm

To date, no safety signals of concern have emerged and none of the participants have dropped out from the study.

Key Points: 
  • To date, no safety signals of concern have emerged and none of the participants have dropped out from the study.
  • Goldberg brings more than 20 years of industry experience, working across clinical development, drug discovery and medical genetics.
  • Prior to this, Dr. Goldberg served in various roles at Xenon Pharmaceuticals including Senior VP, Clinical Development.
  • Michael R. Hayden, CEO and Founder of Prilenia , commented: \xe2\x80\x9cWe are delighted that Dr. Y Paul Goldberg joins the Prilenia team.

Taysha Gene Therapies Expands Leadership Team with the Appointment of Chief Development Officer

Thursday, May 13, 2021 - 12:00pm

b'Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the most recent addition to its leadership team with the appointment of industry veteran Mary Newman as Chief Development Officer.

Key Points: 
  • b'Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the most recent addition to its leadership team with the appointment of industry veteran Mary Newman as Chief Development Officer.
  • Her decades of experience in all key aspects of drug development, particularly in gene therapy and rare disease, will be invaluable as we continue to grow our business.\xe2\x80\x9d\nMs.
  • Newman joins Taysha with more than 30 years of experience in regulatory affairs and research and development within the biotechnology industry, focusing on rare diseases.
  • \xe2\x80\x9cTaysha is well-positioned to be a leader in developing disease-modifying gene therapies for patients with monogenic CNS diseases.

Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update

Thursday, May 13, 2021 - 12:00pm

This will precede multiple anticipated clinical and research milestones across our portfolio in 2021, including interim updates from all three clinical-stage CAR T programs: PBCAR0191, PBCAR20A, and PBCAR269A.

Key Points: 
  • This will precede multiple anticipated clinical and research milestones across our portfolio in 2021, including interim updates from all three clinical-stage CAR T programs: PBCAR0191, PBCAR20A, and PBCAR269A.
  • Since the December 2020 interim data update, additional patients have been dosed with PBCAR0191 following enhanced lymphodepletion (eLD)1.
  • In February 2021, the study began enrolling patients into its highest dose cohort, dose level 3 at 6.0 \xc3\x97 106 cells/kg and Precision expects to provide an interim update in 2021.
  • The Company expects to provide an update in mid-2021.\nExecutive Leadership: In April 2021, Precision announced that it has initiated a CEO transition plan for Co-Founder and Chief Executive Officer, Matt Kane.

The “Rare Disease Company Coalition” Launches to Share the Unique Challenges and Promise of Rare Disease Therapy Development to Support Continued Progress and Patient Access

Thursday, May 13, 2021 - 12:00pm

b'The Rare Disease Company Coalition , a unified voice of life science companies committed to discovering, developing and delivering rare disease treatments, today announced their organizational launch.

Key Points: 
  • b'The Rare Disease Company Coalition , a unified voice of life science companies committed to discovering, developing and delivering rare disease treatments, today announced their organizational launch.
  • This first-of-its-kind alignment of organizations will inform and help educate policymakers on the unique circumstances facing life science companies when developing and bringing to market therapies for very small and differentiated patient populations.
  • Companies focused on rare diseases take on an outsized commitment to and risk in research and development.
  • In 2020, Rare Disease Company Coalition members invested more than $4.1 billion in research and development, representing approximately 65 percent of their annual operating budgets.